Repligen's Q4 performance exceeded expectations but the 2026 guidance was below market expectations

Waltham, Massachusetts - On Tuesday, Repligen Corporation (NASDAQ:RGEN) announced its fourth-quarter results that exceeded analyst expectations.

Due to guidance for 2026 being below Wall Street forecasts, the company’s stock fell 0.72% in pre-market trading.

The biotech company’s adjusted earnings per share for the quarter were $0.49, surpassing the consensus estimate of $0.44.

Revenue reached $197.91 million, beating expectations of $192.89 million, representing an 18% year-over-year increase, with a 14% organic growth rate. Strong quarterly performance was mainly driven by growth in the company’s analytical and protein businesses.

For fiscal 2026, Repligen issued an EPS guidance of $1.93 to $2.01, below the analyst consensus of $2.07. The midpoint of $1.97 is 5% lower than expected.

The company projects revenue of $810 million to $840 million, with a midpoint of $825 million, slightly above market expectations of $823.9 million. This guidance reflects a 10% to 14% reported revenue growth, including a two-percentage-point negative impact from gene therapy.

President and CEO Olivier Loeillot stated, “We closed 2025 with a 14% organic growth rate this quarter, with analytical and protein businesses leading the way. We are very excited about our strong performance in 2025, continuing to expand profit margins while achieving 16% organic non-COVID business growth through our differentiated product portfolio.”

For the full year 2025, Repligen reported revenue of $738 million, a 16% increase year-over-year, and adjusted EPS of $1.71, up from $1.58 in the previous year. The company expects its adjusted operating margin in 2026 to expand by 150 basis points at the median level.

This article was translated with the assistance of artificial intelligence. For more information, please see our Terms of Use.